Patent intelligence · US
US 9278161
Tissue-separating fatty acid adhesion barrier
Tissue-separating fatty acid adhesion barrier
Patent details — US 9278161
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 8, 2016
- Expiration
- Mar 3, 2036
- Applicant
- ATRIUM MEDICAL CORPORATION
- Claims
- 48
- CPC classes
- A61K, A61K9/10, A61P, A61P29/00
Quick answer
US 9278161 (Tissue-separating fatty acid adhesion barrier) is held by ATRIUM MEDICAL CORPORATION. Status: granted. Granted Mar 8, 2016. Expires Mar 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ATRIUM MEDICAL CORPORATION
- Grant date
- Expiration
- Claims
- 48
- CPC classes
- A61K, A61K9/10, A61P, A61P29/00, A61P41/00, A61P43/00
More from ATRIUM MEDICAL CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 11793912
Cross-linked fatty acid-based biomaterials
granted -
US 11166929
Fatty-acid based particles
granted -
US 11097035
Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
granted -
US 11083823
Tissue-separating fatty acid adhesion barrier
granted -
US 10888617
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
granted -
US 10869902
Cured gel and method of making
granted -
US 10864304
Anti-infective antimicrobial-containing biomaterials
granted -
US 10814043
Cross-linked fatty acid-based biomaterials
granted
Frequently asked questions
What is US patent 9278161?
US 9278161 (Tissue-separating fatty acid adhesion barrier) is held by ATRIUM MEDICAL CORPORATION. Status: granted. Granted Mar 8, 2016. Expires Mar 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9278161?
ATRIUM MEDICAL CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 37 pharmaceutical patents for this assignee.
When does US 9278161 expire?
Our index shows an expiration date of Mar 3, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.